Literature DB >> 28576744

Jak Stat signaling and cancer: Opportunities, benefits and side effects of targeted inhibition.

Bernd Groner1, Viktoria von Manstein2.   

Abstract

The effects of Jak Stat signaling and the persistent activation of Stat3 and Stat5 on tumor cell survival, proliferation and invasion have made the Jak Stat pathway a favorite target for drug development and cancer therapy. This notion was strengthened when additional biological functions of Stat signaling in cancer and their roles in the regulation of cytokine dependent inflammation and immunity in the tumor microenvironment were discovered. Stats act not only as transcriptional inducers, but affect gene expression via epigenetic modifications, induce epithelial mesenchymal transition, generate a pro-tumorigenic microenvironment, promote cancer stem cell self-renewal and differentiation, and help to establish the pre-metastatic niche formation. The effects of Jak Stat inhibition on the suppression of pro-inflammatory responses appears most promising and could become a strategy in the prevention of tumor progression. The direct and mediated mechanisms of Jak Stat signaling in and on tumors cells, the interactions with other signaling pathways and transcription factors and the targeting of the functionally crucial secondary modifications of Stat molecules suggest novel approaches to the future development of Jak Stat based cancer therapeutics.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Immune therapy; Jak stat signaling in cancer; Signaling pathway interactions; Targeted therapeutics; Tumor microenvironment

Mesh:

Substances:

Year:  2017        PMID: 28576744     DOI: 10.1016/j.mce.2017.05.033

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  86 in total

1.  Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling.

Authors:  Lei Zhang; Qiaoling Song; Xinxin Zhang; Li Li; Ximing Xu; Xiaohan Xu; Xiaoyu Li; Zhuoya Wang; Yuxi Lin; Xin Li; Mengyuan Li; Fan Su; Xin Wang; Peiju Qiu; Huashi Guan; Yu Tang; Wenfang Xu; Jinbo Yang; Chenyang Zhao
Journal:  Invest New Drugs       Date:  2019-05-14       Impact factor: 3.850

Review 2.  Pancreatic Cancer: Recent Progress of Drugs in Clinical Trials.

Authors:  Zhiyi Zhang; Jie Song; Cao Xie; Jun Pan; Weiyue Lu; Min Liu
Journal:  AAPS J       Date:  2021-02-12       Impact factor: 4.009

Review 3.  Transcription factors in colorectal cancer: molecular mechanism and therapeutic implications.

Authors:  Hui Xu; Lei Liu; Weilin Li; Duowu Zou; Jun Yu; Lifu Wang; Chi Chun Wong
Journal:  Oncogene       Date:  2020-12-15       Impact factor: 9.867

4.  A thiazole-derived oridonin analogue exhibits antitumor activity by directly and allosterically inhibiting STAT3.

Authors:  Xiaofei Shen; Lin Zhao; Peihao Chen; Yanqiu Gong; Dingdong Liu; Xia Zhang; Lunzhi Dai; Qingxiang Sun; Jizhong Lou; Zhong Jin; Baohua Zhang; Dawen Niu; Ceshi Chen; Xiangbing Qi; Da Jia
Journal:  J Biol Chem       Date:  2019-10-08       Impact factor: 5.157

5.  Stress-induced phosphoprotein 1 facilitates breast cancer cell progression and indicates poor prognosis for breast cancer patients.

Authors:  Lizhi Lin; Jialiang Wen; Bangyi Lin; Erjie Xia; Chen Zheng; Lechi Ye; Yinghao Wang; Ouchen Wang; Yizuo Chen
Journal:  Hum Cell       Date:  2021-03-04       Impact factor: 4.174

6.  Oncogenic Pathways and Loss of the Rab11 GTPase Synergize To Alter Metabolism in Drosophila.

Authors:  Yingchao Nie; Shiyan Yu; Qi Li; Niraj K Nirala; Alla Amcheslavsky; Yvonne J K Edwards; Patrick W Shum; Zhong Jiang; Wei Wang; Biliang Zhang; Nan Gao; Y Tony Ip
Journal:  Genetics       Date:  2019-06-18       Impact factor: 4.562

7.  Downregulation of miR-19a inhibits the proliferation and promotes the apoptosis of osteosarcoma cells by regulating the JAK2/STAT3 pathway.

Authors:  Jiangqiang Chen; Zuhui Chen
Journal:  Oncol Lett       Date:  2020-08-28       Impact factor: 2.967

Review 8.  Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders.

Authors:  Geoffrey Shouse; Liana Nikolaenko
Journal:  Curr Hematol Malig Rep       Date:  2019-12       Impact factor: 3.952

Review 9.  PD-1/PD-L1 pathway: current researches in cancer.

Authors:  Yanyan Han; Dandan Liu; Lianhong Li
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

Review 10.  Outcompeting cancer.

Authors:  Medhavi Vishwakarma; Eugenia Piddini
Journal:  Nat Rev Cancer       Date:  2020-01-13       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.